InsiderTrades

Form 4 for FDMT 4D Molecular Therapeutics, Inc.

Accepted 2025-12-23 00:00:00 ET · period of report 2025-12-20 · accession 0001193125-25-331299 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2025-12-23 2025-12-20 FDMT Gupta Ashoo VP, Fin, Ctrl S - Sale+OE $8.68 -389 46.4K -0.8% -$3,377
DM 2025-12-23 2025-12-20 FDMT Gupta Ashoo VP, Fin, Ctrl M - OptEx — +1,086 46.5K +2% —
DM 2025-12-23 2025-12-20 FDMT Gupta Ashoo VP, Fin, Ctrl M - OptEx $0.00 -1,086 3,308 -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-20 S D 310 $8.68 46,218 D — —
2 Common Common Stock 2025-12-20 M A 220 — 46,438 D — — (F1) Restricted Stock Units convert into common stock on a one-for-one basis.
3 Common Common Stock 2025-12-20 S D 79 $8.68 46,359 D — —
4 Common Common Stock 2025-12-20 M A 866 — 46,528 D — — (F1) Restricted Stock Units convert into common stock on a one-for-one basis.
5 Derivative Restricted Stock Units 2025-12-20 M D 866 $0.00 12,984 D — · — to — 866 Common Stock (F1) Restricted Stock Units convert into common stock on a one-for-one basis. (F3) The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
6 Derivative Restricted Stock Units 2025-12-20 M D 220 $0.00 3,308 D — · — to — 220 Common Stock (F1) Restricted Stock Units convert into common stock on a one-for-one basis. (F4) The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.